Cariprazine for stubborn depression: two trials agreed it helps, disagreed on dose

Adding cariprazine, an atypical antipsychotic, to an antidepressant that has not fully worked produces a modest but statistically real reduction in depressive symptoms: in the pivotal 2023 phase 3 trial, 1.5 mg/day cut Montgomery-Åsberg Depression Rating Scale (MADRS) scores by 14.1 points at six weeks against 11.5 for placebo [s1]. That is the evidence behind cariprazine's use as an add-on for major depression — but the two positive trials disagree about which dose does the work, and that disagreement is the most useful thing to carry away from them [s1][s2].

What "adjunctive" means here

Roughly a third to a half of people treated for major depression do not respond adequately to the first antidepressant. One option is to add a second drug from a different class rather than switch, and several antipsychotics are used this way. Cariprazine — described in the trial as a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist — is one of them [s1]. Both trials tested it not on its own but bolted onto an antidepressant the patient was already taking without enough benefit [s1][s2].

The 2023 trial

The pivotal study randomised adults with major depressive disorder and inadequate response to at least one antidepressant, in a 1:1:1 ratio, to placebo, cariprazine 1.5 mg/day, or cariprazine 3.0 mg/day [s1]. The modified intent-to-treat population comprised 751 patients — 249 on placebo, 250 on 1.5 mg/day, and 252 on 3.0 mg/day [s1]. The primary outcome was the change from baseline to week 6 in MADRS total score [s1].

At week 6, the mean MADRS reduction was significantly greater with 1.5 mg/day than placebo (−14.1 versus −11.5), but 3.0 mg/day (−13.1) did not separate from placebo [s1]. The lower dose also beat placebo at weeks 2 and 4 [s1]. On the response threshold — a clinically meaningful drop in symptoms — 44.0% of the 1.5 mg group met it against 34.9% on placebo, while remission rates did not differ significantly between the groups [s1]. The common treatment-emergent adverse events, defined as occurring in at least 5% of a cariprazine group and at twice the placebo rate, were akathisia (a distressing inner restlessness) and nausea [s1].

The earlier trial, which points the other way on dose

The result did not come out of nowhere. A double-blind, placebo-controlled flexible-dose study run from December 2011 to December 2013 had already tested adjunctive cariprazine in adults with an inadequate antidepressant response, randomising 269 to placebo, 274 to 1–2 mg/day, and 276 to 2–4.5 mg/day over eight weeks [s2].

There, the arithmetic flipped. Against placebo, the reduction in MADRS at week 8 was significantly greater with the higher 2–4.5 mg/day band (least-squares mean difference −2.2; adjusted P = .0114) but not with the lower 1–2 mg/day band (−0.9; P = .2404) [s2]. The adverse events reported in at least 10% of the higher-dose group were akathisia (22.3%), insomnia (13.6%), and nausea (12.8%), and no suicide-related adverse events were reported [s2].

The dose wrinkle

Read together, the two trials support the drug and complicate the dose. In 2023 the low dose (1.5 mg) worked and the higher one (3.0 mg) did not; in the earlier study the higher band (2–4.5 mg) worked and the lower one (1–2 mg) did not [s1][s2]. This is not a rare pattern in adjunctive-antipsychotic depression trials, where dose-response curves are often flat or non-monotonic and a numerically larger dose brings more akathisia without more benefit. It is a reason to treat any single trial's "winning" dose as provisional rather than settled, and it sits alongside a wider literature — canvassed in our review of augmentation with aripiprazole in older adults — on how much these add-on strategies actually buy.

How big is the effect

Modest, on the trials' own numbers. The placebo-adjusted MADRS difference was 2.6 points in 2023 and 2.2 points in the earlier study [s1][s2] — real, statistically significant, and small against a scale that runs to 60. The response-rate gap of roughly nine percentage points [s1] is the kind of difference that matters at population scale and can be marginal for an individual, which is why remission — getting genuinely well, not just better — is the harder bar these trials did not clear [s1]. Neither result speaks to whether adding a drug beats switching to a different antidepressant or adding psychotherapy, comparisons these placebo-controlled designs were not built to make; our survey of which psychotherapy works for depression covers the non-drug side.

What to watch

Akathisia is the signal to weigh against the benefit: it was the most common adverse event in both trials [s1][s2] and is the kind of side effect that quietly drives people off a drug. Longer-term maintenance data, head-to-head comparisons against dose-switching, and how the effect holds up outside a trial population are the open questions. This article describes trial results and is not medical advice.

Sources

• Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study — American Journal of Psychiatry, 2023-02-15
• Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder — The Journal of Clinical Psychiatry, 2016-03-01